Efforts are needed to enhance the efficacy of cord blood (CB) transplantation. Laboratory information set the stage for the first and subsequent CB transplants, and will be instrumental in continuing to advance the field. This paper offers a brief understanding of the current state of hematopoietic stem cell (HSC) and hematopoietic progenitor cell (HPC) biology, a look back at laboratory studies leading to the first CB transplants, and a discussion of the possible means to enhance CB transplantation. Results show that physical recovery of greater numbers of HPCs is possible after CB is collected by perfusing the placenta, but how realistic this procedure is for collection of CB to be banked is open to question. We also show that the chemokine stromal cell-derived factor-1/CXCL12 can enhance the ex vivo expansion of CB HPCs beyond that of the combination of SCF, Flt3-ligand and TPO. Advances in cytokine and stromal cell biology, and in intracellular signals mediating the effects of cytokines/stromal cells should be considered in the context of future efforts to enhance functional activities of donor CB HSCs and HPCs and the microenvironmental niche of the recipient, which is required for acceptance and nurturing these HSCs/HPCs.
Introduction
Umbilical cord and placental blood (CB) has been used to treat more than 14 000 patients with a variety of malignant and non-malignant disorders. 1 This capability is based on its content of hematopoietic stem cells (HSCs) and hematopoietic progenitor cells (HPCs), which can replace the blood system of appropriately conditioned recipients. 2 It is only in the last 20 or so years that the life-saving properties of CB were clinically realized. Until the first successful CB transplant was performed on 6 October 1988, 3 an event that reflected in a very large part the ongoing laboratory studies that documented that CB could serve as a potential source of transplantable HSCs/HPCs, 4 CB was used mainly as a screening procedure for evaluating certain blood chemistry parameters of the newborn. Thus, for all intents and purposes before that transplant, CB was considered a waste product of the birthing procedure, and was discarded. Events leading to the first CB transplant have been documented in a number of earlier publications. 1, [5] [6] [7] [8] [9] The purpose of this article is to review in brief the biological laboratory studies and state-of-the-art knowledge at that time, which led to the first series of CB transplants, and to report efforts to enhance collections of HPCs from CB, and to increase expansion of HPCs ex vivo.
Brief understanding of the current state of HSC/HPC biology and gaps in this knowledge A good place to start is what the state-of-the-art knowledge of HSC/HPC biology is today, which then serves as a focal point for where we were over 20 years ago, and where we have to go in the future to enhance the field of CB transplantation. Hematopoiesis, the production of blood cells, is envisioned as a catenated pipeline system that begins with the HSC. 10, 11 HSCs give rise to HPCs, which in turn give rise to the first morphologically recognizable precursor cells within a specific blood lineage, which give rise to specific functional mature blood cells. Although much of what we currently know of hematopoiesis (blood cell production) is based on this concept, it is possible that this catenated paradigm may have to be modified in the future. The new investigative area of induced pluripotent stem cells [12] [13] [14] [15] opens up the question of whether under physiological or stressed conditions the currently envisioned schema of HSC/HPC to mature cell is really a onedirectional flow. Under certain defined conditions, mature cells have been induced to de-differentiate in vitro.
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Whether or not this is a physiological process and occurs in vivo is not known. Much of what we know about HSCs biologically is based on studies in mice, in which an i.v. infusion of a tissue source of HSCs can save the life of a mouse that has been given a lethal dose of irradiation. 16, 17 By phenotypic analysis of the presence and absence of certain antigenic markers and isolation of such cells, it is now possible to save the life of a lethally-irradiated mouse with as few as one purified mouse HSC. CD34 18 (in some cases the presence and absence of SLAM markers can substitute for some of these other markers 19 ) identify mouse BM HSCs. 20 There are also phenotypic markers for various members of mouse HPC populations, including the common lymphoid progenitor, common myeloid progenitor, granulocyte-macrophage progenitor and megakaryocyte erythroid progenitor. 21, 22 These phenotypes are all based on the assumption that the functional activities of these cells can be recapitulated by cells of these respective phenotypes. This means that a single cell purified and isolated with a specific phenotype can, in fact, manifest the functional aspects of the cell with this phenotype. Under non-perturbed/stressed conditions, there is very good evidence that mouse cells with an HSC phenotype have the functional characteristics of that cell (for example, the capacity to save the life of a lethally irradiated mouse), 18, 19 a hallmark characteristic of an HSC. Also, a large percentage of cells with a granulocytemacrophage progenitor phenotype can form a colony containing granulocytes and/or macrophages in semi-solid culture medium in vitro. In vitro colony formation of HPCs is still the gold standard for detecting functional HPCs. Although the phenotypes ascribed to common lymphoid progenitor, common myeloid progenitor and megakaryocyte erythroid progenitor serve as useful markers to begin the evaluation of these HPC types, there is lack of proof that every cell with such a corresponding phenotype of that specific HPC type is in actuality that HPC type. Thus, there is room for improving the phenotypes of the common lymphoid progenitor, common myeloid progenitor and megakaryocyte erythroid progenitor.
The human HSC/HPC system is not nearly as well defined as that of the mouse. Although human HSCs can be found in a population of CD34 þ cells, HSCs are very rare in the CD34 þ cell population. A highly purified CD34 þ cell population is mainly composed of HPCs, and can include other cell types (for example, endothelial cells). Although there are in vitro assays that have in the past been used to identify HSCs, there are not many investigators at present who still consider in vitro assays as a definitive means to detect and evaluate the human HSC with long-term in vivo marrow repopulating capacity. 16, 17 The long-term cultureinitiating cell or cobblestone area-forming cell may detect some cells of the human HSC population, but the system now considered to be the best indicator of identifying a functional human HSC is the in vivo SCID repopulating cell (SRC) assay. 23 In this assay, human cells are assessed for their ability to engraft the hematopoietic system of an SCID mouse that has been given a sublethal dose of irradiation. The key mark of a mouse HSC is that it can save the life of a lethally irradiated mouse. Human cells cannot save the life of a lethally irradiated mouse. Hence, the functional assay for a human HSC, the SRC, is not as rigorous an assay as that for detecting a mouse HSC. Only 1/400-1/800 human CB CD34 þ CD38 À cells engraft the different types of SCID mice. The highest frequency for human SRCs is found using non-obese diabetic-SCID mice that are null for the g-chain of the IL-2 receptor. Some refinements in phenotyping human HSCs have been noted. 24 The most reliable assays for human HPC types are still the in vitro colony-forming unit (CFU)/burst-forming unit (BFU) assays. 16, 17 Human HPCs that give rise to multipotential (CFU-GEMM), granulocyte macrophage (CFU-GM), erythroid (BFU-E) and megakaryocyte (CFU-Meg) type colonies are mainly found in the CD34 þ CD38 þ set of phenotyped cells, but thus far, phenotype markers alone have not been able to separately define the subtypes of HPC (CFU-GEMM, CFU-GM, BFU-E and CFU-Meg). It is clear that we need to better define human HSCs and HPCs phenotypically, but in this process it is important to prove that a specific phenotype definitively recapitulates the appropriate function expected of HSCs/HPCs. Moreover, it is important to appreciate that the phenotypes of cells can change with culture conditions and stress, and that the phenotype that defines an HSC/HPC when the cells are removed from the body may not be adequate to define that specific cell type after culture. Specific examples of this are the CD34 þ phenotype for human HPCs, and the CD34 þ CD38 À phenotype for SRCs. During the ex vivo expansion cultures, there are many more CFUs/BFUs generated than CD34 þ cells, 25 , and Broxmeyer's unpublished observations show that cells with the functional characteristics of HPCs manifest loss of expression of CD34 during culture in vitro. Also, dissociation of the CD34 þ CD38 À phenotype and function of SRC has been described. 26 There are gaps in our understanding of HSC/HPC biology. Inability to adequately and rigorously define human HSCs and HPCs phenotypically makes it very difficult to be sure that the genomics and proteomics attributed to these cells are in fact for HSCs and HPCs specifically. How an HSC decides whether to make more of itself (self-renew) or differentiate into an HPC, through asymmetrical or symmetrical divisions, 27 is likely controlled through cell-cell and cytokine/growth factor-initiated events at the level of specific receptors on HSCs. We still know very little of these processes. Whether the processes are stochastic (random chance), deterministic or a combination of such processes is still being debated. Although it is well established that the placement of HSCs within the context of various stromal cells and extracellular matrix components that comprise the microenvironmental niche is a determining factor, the exact cell types involved are still being discussed, and a detailed mechanistic insight at the cell and intracellular levels is still lacking. Osteoblasts, endothelial cells and fibroblasts are considered relevant players in the microenvironment that control/regulate HSC and HPC function. [28] [29] [30] [31] Different investigative groups have cell types that they favor for the stem/progenitor cell niche, but it is likely that the interactions between these cells form the functional niche. Also, it needs to be determined whether cytokines/growth factors secreted by these niche stromal cells have a role in HSC function, if this is mediated through the local (very close) transfer of cytokines/growth factors between stromal cells and HSCs, or if this cytokine/ growth factor transfer, whether short-or long-distance acting by itself, is a deciding factor, or if in addition other cell-cell contacts are important as partner mediators of selfrenewal, proliferation, survival and differentiation. It is important that we keep an open-mind to all these processes and not lose track of the overall picture by studies that only deal with isolated cell types. A number of intracellular signaling molecules have been implicated in HSC/HPC functions such as self-renewal, survival, proliferation, differentiation and movement, but how these intracellular molecules and pathways interact (for example, cross-talk with each other) to elicit the appropriate end point function, and which of them may be key signaling molecules still requires study.
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Background laboratory studies leading to the first CB transplants When we began our specific studies in the early 1980s to evaluate the feasibility of CB as a source of transplantable HSCs/HPCs, the following facts were known: HPCs of different types were present in CB; CB could be cultured in long-term marrow type assays to generate HPC; and CB HPCs could be expanded to some extent ex vivo (reviewed by Broxmeyer et al. ). It was not clear whether CB contained long-term marrow repopulating/engrafting HSCs (LTMRSCs) and, if so, whether there were enough HSCs/HPCs to be of use in a clinical context to cure malignant and non-malignant disorders of appropriately conditioned recipients. The SRC assay for human HSCs was not yet developed, and it was not clear, even at that time, whether the long-term culture-initiating cell and cobblestone area-forming cell assays that were still in development identified LTMRSCs. As mentioned above, it is now believed that these in vitro assays do not definitively identify LTMRSCs.
The decision to contact Dr Eliane Gluckman to see if she would be willing to attempt the first CB transplant was based on years of meetings, laboratory research efforts, and discussions on which patient population should serve as first recipients of a CB transplant. A number of our findings at that time gave us confidence that single collections of CB could be used for transplantation. Fanconi anemia was picked to be the first disease in which CB was to be tested, and because Dr Gluckman had the best experience with treating patients with Fanconi anemia with BM cells, we asked if she would be willing to do a CB transplant. Thankfully, she agreed, and a child with Fanconi anemia was transplanted with his sister's HLA-identified CB using a protocol that Dr Gluckman had previously established with BM. The first reason for our confidence in CB as a source of transplantable cells was our analysis of large numbers of CB samples that showed numbers of CFU-GM, BFU-E and CFU-GEMM in single CB collections with extensive proliferative capacity, much greater than those we had noted with adult human BM, and that were within the range of those numbers in BM that had been shown by others to be associated with successful BMT. 4 We noted that any attempts to physically separate CB cells resulted in unacceptable losses of these HPCs, which is why we suggested, and Dr Gluckman agreed, that the first CB transplant be carried out with unseparated CB cells that we had learned could be frozen in cryopreserved form, erythrocytes and all, with outstanding recovery of viable nucleated cells and high proliferative HPCs. 4 The first proof-of-principle CB bank was set up in the author's (HEB) laboratory, and this bank was used to store frozen whole CB from a number of HLA-identified siblings. The CB for the first CB transplant, and the next four, as well as two of the next five transplants that came from the author's CB bank were defrosted and infused without washing or separation. As it was possible that we were working with limiting numbers of HSCs/HPCs, we chose to keep losses of these cells to a minimum, by minimally manipulating the cells. Although there was no assay available at that time for human LTMRSCs, we made the assumption that adequate numbers of HSCs were present in these collections on the bases of the extensive numbers and proliferative capacities of HPCs, the capacity to expand ex vivo HPCs from CB, and the capacity of term blood from mice to repopulate the hematopoietic system of congenic mice that were given a lethal dose of irradiation.
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The successful first CB transplants were carried out in a number of different transplant centers with cells from our proof-of-principle bank, which resulted in long-term hematopoietic engraftment of donor cells that verified that single collections of CB not only contained LTMRSCs, but also that there were enough of these HSCs to save the lives of patients requiring an HSC transplant, especially in the context of children and low-weight recipients.
The field has come a long way since the initial first CB transplants performed with cells from the author's bank, and includes the pioneering clinical studies of others on the use of partially HLA-disparate and unrelated CB cells for transplantation, as well as the more recent use of double CB transplants that has greatly enhanced the use of CB for transplantation of adults and higher weight children (reviewed by Broxmeyer and Smith 2 and Tse et al. 33 ). As the initial clinical studies with CB were ongoing, laboratory investigators further confirmed the extensive proliferative and ex vivo expansion capabilities of immature subsets of HSCs/HPCs; the SCID and non-obese diabetic-SCID models for the in vivo assessment of human SRCs/ HSCs were developed and used to determine the superior engrafting capacity of CB, compared with BM and mobilized peripheral blood in these mice with SCID (reviewed by Broxmeyer and Smith 2 ). It has also been determined that CB HSC/HPC could be stored in frozen cryopreserved form for over 15 years 34 (and more recently in the author's laboratory for up to at least 22-23 years; Broxmeyer HE, Cooper SC and Hangoc G, unpublished observations) with excellent recovery and expansion activity of CFU-GM, BFU-E, CFU-GEMM and SRC. Since our initial proof-of-principle CB bank at the Indiana University School of Medicine, more than 400 000 unrelated CBs have been stored frozen by others in more than 100 different CB banks worldwide. 1 This landmark year not only celebrates the twentieth anniversary of the first successful CB transplant, but also marks the first time that more CB transplants have been performed than BM transplants.
Efforts to enhance the efficacy of CB transplantation
There are a number of ways to improve the effectiveness of the limiting numbers of HSC/HPC present single CB collections. The first way is to find a means to collect more cells from the CB/placental blood and, as such, more HSCs/HPCs. This assumes that the current collection procedures are not optimal. The second is to find a way to expand CB HSCs in a clinically relevant manner. The third is to identify means to get the infused CB HSC/HPC to the marrow microenvironment of the recipient in a more efficient manner. This assumes that the homing of the HSCs to their microenvironment niche is not already optimal. Such efforts are described below.
Results

Physical recovery of greater numbers of CB HPCs
Collection of the greatest number of cells from single CBs is dependent on the skill and effort of those performing the collections. We recognized long ago, through the efforts of the late Gordon Douglas, the obstetrician who personally collected a number of the CBs that we were considering for and did use for actual transplantation, that collection of blood from the cord, followed by additional collection from placental blood vessels, always yielded more nucleated cells and HPCs than did those collected only from the cord. 5 In fact, the more the cells that are collected from the cord, the fewer the cells one could isolate from placental vessels, and when the collections from the cord itself seemed suboptimal, there were many more cells capable of being recovered from the placental vessels. Later studies of others, 35 in which perfusion of the placenta resulted in enhanced collection of CB cells and HPCs, are consistent with our findings. 5 In a collaborative study with Drs David M Haas, Jon K Hathaway and Frederick B Stehman from the Department of Obstetrics and Gynecology, Scott Cooper from Broxmeyer's laboratory undertook to see how many HPC could be recovered by perfusion of the placentas, after collection of cells from the cords was finished. As shown in Figure 1a , there were always numerous HPCs left in the placenta after the collection from the cord no longer yielded much blood. In fact, after the collection of blood from the cord was finished, we were able to obtain as many CFU-GM and CFU-GEMM from subsequent perfusion of the placenta as we were able to obtain from the cord itself (Figure 1b) . Thus, after collection of the CB, we had left at least as many HPCs in the placenta as we had collected from the cord. Even though it is clear that collection of blood from the cord itself is not optimal in terms of retrieving HPCs, and likely HSCs, it may not be feasible to set up a perfusion system for use with every CB collection. Our goal was to determine, after the perfusion no longer yielded decent numbers of HPCs, whether we could use agents, such as the HSC/HPC mobilizing agent AMD3100, to further enhance collection of more HPCs and HSCs from the placenta. Owing to the great variability in numbers of HPCs in CB collections from different CB donors, such experiments must be internally controlled, first for effects of the perfusion itself. Unfortunately, we found it difficult to control for what we could attain with perfusion in the absence vs presence of candidate-mobilizing inducers because of variability between different CBs, and such studies are currently on hold until we figure out how best to control within a single CB for the effect of the perfusion itself. Along with such studies, it is also important to be Comparison of absolute numbers of nucleated cells, CFU-GM and CFU-GEMM collected from cord blood and from the same donor's perfused placental blood, expressed as a percentage of the total. CFU-GM-and CFU-GEMM-colony numbers were scored 14 days after incubation at 5% CO 2 and lowered (5%) O 2 tension in 1% methylcellulose medium with 30% fetal bovine, 1 U/ml recombinant human (rhu) EPO, 50 ng/ml rhu SCF, 10 ng/ml rhu and 10 ng/ml each of rhu GM-CSF and IL -3. sure that the procedures used to enhance collection of HSCs/HPCs from CB/placental blood are not associated with unwanted collection of maternal cells. It was once felt that CB transplantation would be non-viable because of the collection of clinically relevant numbers of maternal cells and the unacceptable GVHD that may be elicited by maternal cell contamination of the CB, but this turned out not to be a significant concern. In fact, the level of GVHD elicited by CB transplantation was and still is relatively low compared with the use of comparably matched cells from BM. Nevertheless, any new mechanical or chemical procedure that may enhance the collection of HSCs/HPCs from the cord or placenta will have to evaluate the potential for associated collection of maternal cells.
Ex vivo expansion of HSCs/HPCs
Efforts to clinically expand human CB HSCs/HPCs for use in patients has been suboptimal, and additional efforts in this endeavor are warranted. The combination of SCF, Flt3-ligand (FL) and TPO has shown efficacy in a laboratory setting for ex vivo expansion of HPCs and SRCs. 36, 37 We decided to evaluate the effects of stromal cell-derived factor-1 (SDF-1)/CXCL12 on the ex vivo expansion of HPCs from CB CD34 þ cells in the context of SCF, FL and TPO. We chose to evaluate SDF-1/ CXCL12 because, in addition to its chemotactic/homing activity, SDF-1/CXCL12 has been found to act as a survival/antiapoptotic factor for human and mouse HPCs and mouse HPCs, [38] [39] [40] and acts as a survival factor and proliferation stimulus for mouse embryonic stem cell lines. 41 As seen in Table 1 , the combination of SCF, FL and TPO resulted in respective increases in CFU-GM and CFU-GEMM ranging from 4.3-to 29.2-fold and from 1.2-to 6.5-fold. The addition of SDF-1/CXCL12 to the cytokine mixture of SCF, FL and TPO, respectively, increased CFU-GM and CFU-GEMM to ranges of 8.9-to 59.4-fold and 2.3-to 14.7-fold. This resulted in SDF-1/ CXCL12 increasing the ex vivo expansion of CFU-GM and CFU-GEMM, respectively, by 1.8±0.2 and 2.2±0.3 (mean ± 1 s.e.m.) fold above that of the combination of SCF, FL and TPO. Whether SDF-1/CXCL12 may enhance the ex vivo expansion of CB SRC (a measure of HSC), or exactly how SDF-1/CXCL12 is working in this context is not known. It may be acting through a survival/antiapoptotic mechanism, or through enhancing self-renewal capacity, as it is not known whether SDF-1/CXCL12 enhances the in vitro replating efficiency of HPCs, 42 a measure of limited self-renewal capacity, or through other means. More effort in this area is warranted.
CD26/Dipeptidylpeptidase IV CD26/Dipeptidylpeptidase IV (DPPIV) truncates SDF-1/ CXCL12 into a molecule that does not have chemotactic activity for HPCs and HSCs. Moreover, the truncated SDF-1/CXCL12 blocks the chemotactic activity of SDF-1/ CXCL12. 43 Inhibition or deletion of CD26/DPPIV enhances the chemotactic activity of SDF-1/CXCL12 for HPCs/HSCs, and the homing/engrafting capacity of HSCs. [44] [45] [46] Efforts to enhance the homing/engrafting capacity is underway in a number of centers. One means to achieve this goal may be through the inhibition of CD26/ DPPIV through the short-term ex vivo exposure of target cells to small peptide CD26/DPPIV inhibitors (for example, 15 min to 1 h) before the infusion of cells into conditioned recipients, as reported for mouse BM HSCs into lethally irradiated mice, 44, 45 or human CD34 þ CB cells into sublethally irradiated non-obese diabetic/SCID mice. 47, 48 Alternatively, one may consider pretreating the recipient with the small peptide inhibitors. However, in this scenario, caution is warranted, as we do not know all the effects of these inhibitors, and it is possible that, if not administered as a correct timing to the transplant, it might accelerate the endogenous recovery of recipient cells.
From a practical point of view, it is possible that the inhibition or deletion of CD26/DPPIV will enhance the ex vivo expansion activity of SDF-1/CXCL12 for HPCs in a scenario similar to that evaluated in Table 1 , and may act to also enhance the expansion of SRCs/HSCs.
Concluding thoughts
The field of CB transplantation has come a long way since the first transplant more than 20 years ago. Moreover, the biology of HSCs and HPCs has also advanced significantly in this time frame. The key to enhancing the efficacy of CB transplantation is to take advantage of new laboratory findings and assess them for potential clinical translation benefit. In this context, we are beginning to better understand the cytokines and microenvironmental niches that have a role in the regulation of HSCs and HPCs, as well as the intracellular signaling molecules that mediate cytokine and stromal cell effects on the self-renewal, proliferation, survival and migration/homing of HSCs. Integrating this Table 1 Influence of stromal cell-derived factor-1 (SDF-1)/ CXCL12 on cord blood hematopoietic progenitor cells (HPCs) expanded ex vivo in the presence of SCF, Flt3-ligand (FL) and TPO Fold increase of HPC in suspension culture with SCF, FL, TPO in the presence of control medium or SDF-1/CXCL12. CD34 + cord blood cells were isolated and set up for colony-forming unit (CFU)-GM/CFU-GEMM assay at 250 500 and 1000 cells/ml in 1% methylcellulose culture medium in the presence of 1 U/ml rhu EPO, 50 ng/ml rhu SCF, 10 ng/ml rhu GM-CSF and 10 ng/ml rhu IL-3 as noted in the legend to Figure 1 , or were placed in suspension culture medium at 10 3 CD34 + cells/ml in the presence of 50 ng/ml rhu SCF, 100 ng/ml FL and 10 ng/ml rhu TPO in the presence of either control medium or 100 ng/ml rhu SDF-1/CXCL12. After 7 days in suspension culture, cells were counted and plated at various dilutions, in 1% methylcellulose as noted above for CFU-GM/CFU-GEMM assay. All cultures were incubated in a humidified chamber at 5% CO2 and lowered (5%) O2 tension. The data are shown for four experiments as fold increase of CFU-GM and CFU-GEMM after suspension culture compared with input numbers. The numbers in parentheses are the fold change for SDF-1/CXCL12 compared with control medium above that seen with SCF, FL and TPO.
information into a practical setting will likely benefit the field of CB transplantation.
